SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue Fromntinuing

Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-08-17
Original SEC Filing: Click here


Webplus: SKBI/20100817/8-K/2_EX-99.1/000.htm SEC Original: v194408_ex99-1.htm
Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue Fromntinuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share;mpany reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XIAN, CHINA August 17, 2010 — -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) (“Skystar” or the “Company”),




Webplus: SKBI/20100817/8-K/1/000.htm SEC Original: v194408_8k.htm
FORM 8-K CURRENT REPORTte of report (Date of earliest event reported): August 17, 2010YSTAR BIO-PHARMACEUTICALMPANY Nevada 001-34394 33-0901534 (State or other jurisdiction oforporation or organization) (Commission File No.) (IRS Employer Identification No.) Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian, Shaanxi Province, P.R. China



Company Information:

Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-08-17CIK: 0001076939, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
RM 10601, JIEZUO PLAZA, NO. 4, FENGHUI ROAD SOUTH, GAOXIN DISTRICT
XIAN PROVINCE

Home Page Forums

By | 2016-02-05T04:05:49+00:00 August 17th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar